CY1115961T1 - Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) - Google Patents
Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)Info
- Publication number
- CY1115961T1 CY1115961T1 CY20151100093T CY151100093T CY1115961T1 CY 1115961 T1 CY1115961 T1 CY 1115961T1 CY 20151100093 T CY20151100093 T CY 20151100093T CY 151100093 T CY151100093 T CY 151100093T CY 1115961 T1 CY1115961 T1 CY 1115961T1
- Authority
- CY
- Cyprus
- Prior art keywords
- maline
- crystal
- orvepitant maleate
- anhydrated
- anhydrated form
- Prior art date
Links
- IPACOHTZCSBGBV-WUXDIRCFSA-N (2r,4s)-4-[(8as)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperidine-1-carboxamide;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2C[C@H]3N(C(CC3)=O)CC2)=CC=C(F)C=C1C IPACOHTZCSBGBV-WUXDIRCFSA-N 0.000 title 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
Η εφεύρεση αφορά άνυδρη κρυσταλλική μηλεϊνική ορβεπιτάντη (Μορφή 1), φαρμακευτικά σκευάσματα που περιλαμβάνουν την ίδια, τη χρήση της στη θεραπεία και τις διαδικασίες για την παρασκευή της ίδιας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0806652.4A GB0806652D0 (en) | 2008-04-11 | 2008-04-11 | Anhydrous crystal form of orvepitant maleate |
| EP09731234.2A EP2297152B1 (en) | 2008-04-11 | 2009-04-09 | Anhydrous crystal form of orvepitant maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115961T1 true CY1115961T1 (el) | 2017-01-25 |
Family
ID=39433527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100093T CY1115961T1 (el) | 2008-04-11 | 2015-01-29 | Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8309553B2 (el) |
| EP (1) | EP2297152B1 (el) |
| JP (2) | JP5875863B2 (el) |
| KR (1) | KR20110002090A (el) |
| CN (1) | CN102066376B (el) |
| AR (1) | AR071311A1 (el) |
| AU (1) | AU2009235440B2 (el) |
| BR (1) | BRPI0911678B8 (el) |
| CA (1) | CA2721119C (el) |
| CL (1) | CL2009000876A1 (el) |
| CY (1) | CY1115961T1 (el) |
| DK (1) | DK2297152T3 (el) |
| EA (1) | EA017082B1 (el) |
| ES (1) | ES2529295T3 (el) |
| GB (1) | GB0806652D0 (el) |
| HR (1) | HRP20141196T1 (el) |
| IL (1) | IL208597A0 (el) |
| MX (1) | MX2010011152A (el) |
| PE (1) | PE20091839A1 (el) |
| PL (1) | PL2297152T3 (el) |
| PT (1) | PT2297152E (el) |
| RS (1) | RS53732B1 (el) |
| SI (1) | SI2297152T1 (el) |
| TW (1) | TW201002714A (el) |
| UY (1) | UY31758A (el) |
| WO (1) | WO2009124996A1 (el) |
| ZA (1) | ZA201007120B (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8139718B2 (en) * | 2007-10-30 | 2012-03-20 | Elekta Ab (Publ) | Radiotherapy apparatus |
| GB0806652D0 (en) * | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| WO2014057003A1 (en) * | 2012-10-11 | 2014-04-17 | Nerre Therapeutics Limited | Novel uses |
| RS59313B1 (sr) * | 2016-01-08 | 2019-10-31 | Nerre Therapeutics Ltd | Orvepitant za lečenje hroničnog kašlja |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| KR20250069704A (ko) | 2017-06-30 | 2025-05-19 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| TWI785098B (zh) | 2017-08-18 | 2022-12-01 | 開曼群島商科賽睿生命科學公司 | Tg02之多晶型 |
| AU2021246889A1 (en) * | 2020-04-03 | 2022-10-13 | Nerre Therapeutics Limited | An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS) |
| MX2022014901A (es) | 2020-06-02 | 2023-01-18 | Nerre Therapeutics Ltd | Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| AU2007253704A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
| US20100308579A1 (en) * | 2007-11-02 | 2010-12-09 | Entegris, Inc. | Integral face seal |
| GB0806652D0 (en) * | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
-
2008
- 2008-04-11 GB GBGB0806652.4A patent/GB0806652D0/en not_active Ceased
-
2009
- 2009-04-08 AR ARP090101268A patent/AR071311A1/es not_active Application Discontinuation
- 2009-04-08 PE PE2009000500A patent/PE20091839A1/es not_active Application Discontinuation
- 2009-04-09 MX MX2010011152A patent/MX2010011152A/es active IP Right Grant
- 2009-04-09 HR HRP20141196AT patent/HRP20141196T1/hr unknown
- 2009-04-09 TW TW098111752A patent/TW201002714A/zh unknown
- 2009-04-09 RS RS20150008A patent/RS53732B1/sr unknown
- 2009-04-09 BR BRPI0911678A patent/BRPI0911678B8/pt active IP Right Grant
- 2009-04-09 PL PL09731234T patent/PL2297152T3/pl unknown
- 2009-04-09 WO PCT/EP2009/054295 patent/WO2009124996A1/en not_active Ceased
- 2009-04-09 EA EA201071183A patent/EA017082B1/ru not_active IP Right Cessation
- 2009-04-09 US US12/936,407 patent/US8309553B2/en active Active
- 2009-04-09 CA CA2721119A patent/CA2721119C/en active Active
- 2009-04-09 EP EP09731234.2A patent/EP2297152B1/en active Active
- 2009-04-09 AU AU2009235440A patent/AU2009235440B2/en active Active
- 2009-04-09 JP JP2011503450A patent/JP5875863B2/ja active Active
- 2009-04-09 CN CN200980122132.9A patent/CN102066376B/zh active Active
- 2009-04-09 PT PT9731234T patent/PT2297152E/pt unknown
- 2009-04-09 SI SI200931110T patent/SI2297152T1/sl unknown
- 2009-04-09 DK DK09731234.2T patent/DK2297152T3/da active
- 2009-04-09 KR KR1020107025211A patent/KR20110002090A/ko not_active Ceased
- 2009-04-09 ES ES09731234.2T patent/ES2529295T3/es active Active
- 2009-04-09 CL CL2009000876A patent/CL2009000876A1/es unknown
- 2009-04-13 UY UY0001031758A patent/UY31758A/es not_active Application Discontinuation
-
2010
- 2010-10-06 ZA ZA2010/07120A patent/ZA201007120B/en unknown
- 2010-10-10 IL IL208597A patent/IL208597A0/en active IP Right Grant
-
2014
- 2014-06-09 JP JP2014118775A patent/JP2014205688A/ja active Pending
-
2015
- 2015-01-29 CY CY20151100093T patent/CY1115961T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115961T1 (el) | Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) | |
| CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
| MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
| CY1115199T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| TW200605870A (en) | Topical methadone compositions and methods for using the same | |
| MA32568B1 (fr) | Formulations pharmaceutiques contenant des ligands de recepteur de dopamine | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| MA32544B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| CY1116840T1 (el) | Χρηση 24-norudca | |
| CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
| CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
| NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
| DK1962815T3 (da) | Anvendelse af filmdannende hårplejepolymerer fra gruppen polyurethaner og farmaceutiske tilberedninger og plastre indeholdende nævnte polymerer | |
| TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| UA112981C2 (uk) | Варіант людського gdnf |